drugset / Trial / NCT05160740

Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer

NCT05160740

Unknown 348 enrolled Zhujiang Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

The of this study is to explore the clinical outcomes of indocyanine green molecular fluorescence imaging in local resection of primary hepatocellular carcinoma (CNLC Ⅰa stage).

Timeline

Start
2021-09-23
Primary completion
2022-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent Other

Indications